Clavis Pharma ASA

Head Office:
Parkveien 53 B
NO-0256 Oslo
Norway

Tel: +47 24 11 09 50
Fax: +47 24 11 09 51
Org.nr: 983 733 506 MVA
mail@clavispharma.com

Disclaimer

Welcome to Clavis Pharma

The Key to Superior Pharmaceuticals

Clavis Pharma ASA is a clinical stage oncology focused pharmaceutical company based in Oslo, Norway, with a portfolio of novel anti-cancer drugs in development. These potential breakthough products are New Chemical Entities (NCEs) made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry to introduce new properties to already established, commercially successful drugs. Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. 

News & Events

NEW DATE FOR PRESENTATION OF FOURTH QUARTER REPORT 2009

Clavis Pharma ASA (ticker = Clavis) will present the fourth quarter report and preliminary results for 2009 on Wednesday 17 Februray 2010, changed from Thursday 18 February 2010 as per earlier announcement.

Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer

Clavis Pharma (OSE: CLAVIS); the Norwegian cancer drug development company, announced today that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in October last year.   

Clavis Pharma appoints Olav Hellebø as Chief Executive Officer

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announced today that it has appointed Olav Hellebø as its new Chief Executive Officer (CEO). Mr Hellebø, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mr Hellebø will take up his position on 1st February 2010.